CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 96 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05340764
NCT05340764Phase 4Completed
CompareCT.gov

Safety, Efficacy, and Cost-effectiveness of a Reduced Infliximab Infusion Time Protocol

Washington University School of Medicine·interventional·Posted Apr 22, 2022·Updated Aug 29, 2024

In Brief

A Phase 4 clinical trial evaluating Infliximab for Inflammatory Bowel Diseases. Completed, enrolled 96 participants across 1 site.

Detailed Summary

Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate. The investigators would like to see if the infusion can be given over 1 hour. The investigators expect that increasing the rate of infusion WILL NOT lead to an increase in infusion reactions and will be just as safe and effective as the standard 2 hours dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedApr 22, 2022
Enrollment StartAug 1, 2020
Primary CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.2 years ago

Interventions

Infliximabdrug

Infliximab is an effective and commonly used medication to treat patients with IBD